Lisata Therapeutics eliminates President & CBO role, terminates David Slack effective May 1, 2023

LISATA THERAPEUTICS, INC.

Position of President and Chief Business Officer eliminated; David Slack terminated immediately.
Slack resigned from Board of Directors per employment agreement.
Severance: $478,400 over 12 months; bonus of $239,200 (50% of base salary) paid over same period.
Additional lump sum of $24,134 for earned pay, PTO, and expenses; COBRA assistance provided.
Vested option exercise period extended to three years post-termination or remaining term, whichever shorter.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Slack

President and Chief Business Officer

LSTA · LISATA THERAPEUTICS, INC.

Effective: 2023-05-01
Filed: May 1, 2023, 7:59 PM ET

On May 1, 2023, Lisata Therapeutics, Inc. (the “Company”), after a careful review of capital utilization and prioritization, eliminated the position of President and Chief Business Officer, and terminated the employment of Mr. David Slack, effective immediately.

Departed

David Slack

Director

LSTA · LISATA THERAPEUTICS, INC.

Effective: 2023-05-01
Filed: May 1, 2023, 7:59 PM ET

Mr. Slack has effectively resigned from the Company’s Board of Directors as of May 1, 2023 pursuant to the terms of his Employment Agreement.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Slack was terminated as President and Chief Business Officer at LISATA THERAPEUTICS, INC..

Action: terminated
Role: President and Chief Business Officer

Exact text from the filing

On May 1, 2023, Lisata Therapeutics, Inc. (the “Company”), after a careful review of capital utilization and prioritization, eliminated the position of President and Chief Business Officer, and terminated the employment of Mr. David Slack, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Slack resigned as Director at LISATA THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

Mr. Slack has effectively resigned from the Company’s Board of Directors as of May 1, 2023 pursuant to the terms of his Employment Agreement.

View on SEC.gov

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-23-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.